GPP
ALNY icon

Great Point Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Great Point Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$21.9M – 41
2022
Q2 		$21.9M Buy
+150,000
New +$21.3M 5.25% 5
2017
Q4 		– Sell
-250,000
Closed -$29.4M – 40
2017
Q3 		$29.4M Buy
+250,000
New +$21.3M 5.71% 5

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Great Point Partners's ALNY Position: Q1 2019 in Review

Great Point Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 40,197 shares — an estimated $2.93M sold.

Great Point Partners first reported a position in ALNY in Q4 2016 and held it in 6 quarters. The position peaked at $26.3M in Q3 2018. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • Great Point Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Great Point Partners sold 40,197 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $2.93M.
  • Great Point Partners first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 6 quarters.
  • Great Point Partners's Alnylam Pharmaceuticals position peaked at $26.3M in Q3 2018.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.